Bristol-Myers Squibb (BMY) Tops Q1 EPS by 23c, Affirms EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Bristol Myers Squibb Reports Strong First Quarter 2020 Financial Results
May 7, 2020 6:59 AM EDTReports First Quarter Revenues of $10.8 Billion, an Increase of 82%; On a Pro Forma Basis, Revenue Increase of 13% or 8% Excluding Impact of COVID-19 Posts GAAP Loss Per Share of $0.34 and Non-GAAP EPS of $1.72 Achieves Multiple Significant Clinical and Regulatory Milestones Across Portfolio Adjusts 2020 GAAP EPS Guidance Range to $0.37-$0.57 and Affirms 2020 and 2021 Non-GAAP EPS Guidance Continues Progress on Integration Initiatives; $2.5B Synergy Target Remains on Track Contributes to Global COVID-19 Pandemic Response Through Research, Expansion of U.S. Patient Support Program and Support to... More
